Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Price Vision Group
Study ID
NCT04051463
Phase
PHASE2/PHASE3
Status
Completed

Conditions

  • Fuchs Endothelial Dystrophy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.

Key Dates

Start date
Aug 5, 2019
Status verified
Sep 2021
Primary completion
Jul 1, 2020
Completion
Jul 1, 2020

Study Design

Enrollment
29 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Netarsudil
    A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.
  • Placebo Comparator: Placebo
    A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.

Primary Outcome Measure

Change in Central Corneal Thickness [ Time Frame: 1 month ]

Locations (1)

FacilityCityStateZIPSite coordinators
Price Vision GroupIndianapolisIndiana46260-

Find similar trials in Indianapolis, IN

By research site
Price Vision Group· Indianapolis, IN

Related Studies